Poseida Therapeutics, Inc. Operating Expenses
Poseida Therapeutics, Inc. reported Operating Expenses of $52.01 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2024-11-07
- Poseida Therapeutics, Inc. operating expenses for the quarter ending 2024-09-30 was $52.01M, a 14.11% increase year-over-year.
- Poseida Therapeutics, Inc. operating expenses for the quarter ending 2024-06-30 was $57.73M, a 20.60% increase year-over-year.
- Poseida Therapeutics, Inc. operating expenses for the quarter ending 2024-03-31 was $52.72M, a 5.74% increase year-over-year.
- Poseida Therapeutics, Inc. operating expenses for the quarter ending 2023-12-31 was $50.90M, a 17.64% increase year-over-year.
- Poseida Therapeutics, Inc. operating expenses for fiscal 2023 was $194.21M, a 1.98% increase from fiscal 2022.
- Poseida Therapeutics, Inc. operating expenses for fiscal 2022 was $190.44M, a 10.30% increase from fiscal 2021.
- Poseida Therapeutics, Inc. operating expenses for fiscal 2021 was $172.65M, a 36.43% increase from fiscal 2020.
- Poseida Therapeutics, Inc. operating expenses for fiscal 2020 was $126.55M, a 47.95% increase from fiscal 2019.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2024-09-30 | $52.01M 10-Q · filed 2024-11-07 | $109.73M derived: sum of 2 quarters · filed 2024-11-07 | $162.45M 10-Q · filed 2024-11-07 | $213.36M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $57.73M 10-Q · filed 2024-08-05 | $110.45M 10-Q · filed 2024-08-05 | $161.35M derived: sum of 3 quarters · filed 2024-08-05 | $206.93M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $52.72M 10-Q · filed 2024-05-14 | $103.62M derived: sum of 2 quarters · filed 2024-05-14 | $149.20M derived: sum of 3 quarters · filed 2024-11-07 | $197.06M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $50.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $96.48M derived: sum of 2 quarters · filed 2024-11-07 | $144.35M derived: sum of 3 quarters · filed 2024-11-07 | $194.21M 10-K · filed 2024-03-07 |
| 2023-09-30 | $45.57M 10-Q · filed 2024-11-07 | $93.44M derived: sum of 2 quarters · filed 2024-11-07 | $143.30M 10-Q · filed 2024-11-07 | $186.57M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $47.87M 10-Q · filed 2024-08-05 | $97.73M 10-Q · filed 2024-08-05 | $141.00M derived: sum of 3 quarters · filed 2024-08-05 | $185.53M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $49.86M 10-Q · filed 2024-05-14 | $93.13M derived: sum of 2 quarters · filed 2024-05-14 | $137.66M derived: sum of 3 quarters · filed 2024-05-14 | $181.90M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $43.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $87.80M derived: sum of 2 quarters · filed 2024-03-07 | $132.04M derived: sum of 3 quarters · filed 2024-03-07 | $190.44M 10-K · filed 2024-03-07 |
| 2022-09-30 | $44.53M 10-Q · filed 2023-11-09 | $88.77M derived: sum of 2 quarters · filed 2023-11-09 | $147.17M 10-Q · filed 2023-11-09 | $195.88M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $44.24M 10-Q · filed 2023-08-08 | $102.64M 10-Q · filed 2023-08-08 | $151.36M derived: sum of 3 quarters · filed 2023-08-08 | $192.95M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $58.40M 10-Q · filed 2023-05-09 | $107.11M derived: sum of 2 quarters · filed 2023-05-09 | $148.70M derived: sum of 3 quarters · filed 2023-05-09 | $193.58M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $48.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $90.31M derived: sum of 2 quarters · filed 2023-03-09 | $135.19M derived: sum of 3 quarters · filed 2023-03-09 | $172.65M 10-K · filed 2023-03-09 |
| 2021-09-30 | $41.59M 10-Q · filed 2022-11-10 | $86.47M derived: sum of 2 quarters · filed 2022-11-10 | $123.93M 10-Q · filed 2022-11-10 | $159.29M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $44.88M 10-Q · filed 2022-08-11 | $82.34M 10-Q · filed 2022-08-11 | $117.70M derived: sum of 3 quarters · filed 2022-08-11 | $151.18M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $37.46M 10-Q · filed 2022-05-12 | $72.82M derived: sum of 2 quarters · filed 2022-05-12 | $106.30M derived: sum of 3 quarters · filed 2022-05-12 | $135.74M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $35.36M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $68.83M derived: sum of 2 quarters · filed 2022-03-10 | $98.28M derived: sum of 3 quarters · filed 2022-03-10 | $126.55M 10-K · filed 2022-03-10 |
| 2020-09-30 | $33.47M 10-Q · filed 2021-11-09 | $62.92M derived: sum of 2 quarters · filed 2021-11-09 | $91.19M 10-Q · filed 2021-11-09 | $114.40M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $29.45M 10-Q · filed 2021-08-12 | $57.72M 10-Q · filed 2021-08-12 | $80.93M derived: sum of 3 quarters · filed 2021-08-12 | $101.69M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $28.27M 10-Q · filed 2021-05-11 | $51.48M derived: sum of 2 quarters · filed 2021-05-11 | $72.24M derived: sum of 3 quarters · filed 2021-05-11 | $100.59M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $23.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $43.98M derived: sum of 2 quarters · filed 2021-03-11 | $72.32M derived: sum of 3 quarters · filed 2021-03-11 | $85.53M 10-K · filed 2021-03-11 |
| 2019-09-30 | $20.76M 10-Q · filed 2020-11-12 | $49.11M derived: sum of 2 quarters · filed 2020-11-12 | $62.32M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $28.34M 10-Q · filed 2020-08-20 | $41.56M 10-Q · filed 2020-08-20 |